Holen Sie sich die Stockscreener-App
262.57
2.71%
-7.5164
Ascendis Pharma A S Aktie (ASND) Neueste Nachrichten
Ascendis Pharma (NASDAQ:ASND): A Fitting Candidate for Affordable Growth Investors - ChartMill
Ascendis Pharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference - The Manila Times
Ascendis Pharma (NASDAQ: ASND) officer lines up 3,000-ADS sale for 2026 - Stock Titan
Ascendis to Present Navepegritide Infant Trial Data at ESPE 2026 - The Clinical Trial Vanguard
Ascendis Pharma A/S Trade Ideas — HAM:A710 - TradingView
Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026 - The Manila Times
Ascendis Pharma to Present Sentinel Cohort Data from reACHin Trial of TransCon CNP at ESPE 2026 - Quiver Quantitative
Ascendis Pharma A/S (ASND) Stock Analysis: Unveiling a 16.35% Potential Upside for Investors - DirectorsTalk Interviews
Ascendis Pharma (ASND) Could Be 14% Undervalued Following Yorvipath Reimbursement Progress - simplywall.st
Oppenheimer Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $312 - Moomoo
Ascendis Pharma (ASND) Reimbursement Win Puts Its Fair Value Narrative Back In Focus - Yahoo Finance
Ascendis Pharma (ASND) Settles Patent Fight And Wins Canadian Yorvipath Reimbursement Backing - Yahoo Finance
Ascendis Pharma Director Lars Holtug Executes Sale of 236 Shares at $264.13 Each - Kalkine Media
Stifel Nicolaus Remains a Buy on Ascendis Pharma (ASND) - The Globe and Mail
Ascendis Pharma (ASND) director to sell shares for taxes - Stock Titan
Oppenheimer Adjusts Price Target on Ascendis Pharma to $312 From $304, Maintains Outperform Rating - marketscreener.com
Stifel Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Cuts Target Price to $326 - Moomoo
Ascendis Pharma A/S (ASND) Institutional Ownership 2026 - MarketBeat
Oppenheimer raises Ascendis Pharma stock price target on settlement By Investing.com - Investing.com Australia
BioMarin To Get Royalties From Ascendis Under IP Settlement - Law360
Oppenheimer raises Ascendis Pharma stock price target on settlement - Investing.com
BofA cuts Ascendis Pharma stock price target on settlement impact By Investing.com - Investing.com South Africa
BioMarin announces global settlement with Ascendis - The Pharma Letter
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
A Quick Look at Today's Ratings for Ascendis Pharma A/S(ASND.US), With a Forecast Between $273 to $344 - Moomoo
Ascendis Pharma (ASND) Clears Yuviwel Patent Fight With Global Licensing Deal - simplywall.st
BofA cuts Ascendis Pharma stock price target on settlement impact - Investing.com
Ascendis Pharma (NASDAQ:ASND) Passes Minervini Trend Template and High Growth Momentum Screen - ChartMill
Ascendis Pharma settles patent dispute with US-based Biomarin - medwatch.com
Ascendis Pharma ASND Draws Bullish Targets After Q2 Earnings Surge - timothysykes.com
Ascendis Pharma (NASDAQ: ASND) strikes global YUVIWEL settlement with BioMarin - Stock Titan
Ascendis Pharma A/S and Biomarin Pharmaceutical Inc. Enter Binding Term Sheet for Global Settlement and License Agreement Related to Yuviwel and Navepegritide-Related Products - marketscreener.com
Ascendis to pay 20% Yuviwel royalties in patent settlement with BioMarin - Fierce Pharma
Why Ascendis Pharma (ASND) Stock Is Up Today - Quiver Quantitative
Biomarin nabs big royalties in achondroplasia patent settlement with Ascendis - BioSpace
Ascendis Pharma, Science Applications International And Other Big Stocks Moving Higher On Monday - Benzinga
Jefferies lowers Ascendis Pharma stock price target on settlement - Investing.com
H.C. Wainwright reiterates Ascendis Pharma stock rating at buy By Investing.com - Investing.com Australia
Biomarin, Ascendis Reach Mutually Beneficial Agreement Ending Global Patent Disputes - Yahoo Finance
BioMarin Licenses CNP Program to Ascendis With 20%/18% Royalties, Ends Patent Disputes - TradingView
Ascendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL® (Navepegritide) - Yahoo Finance
Ascendis Pharma A/S (ASND): Investor Outlook Reveals a Promising 27% Upside Potential in Biotech - DirectorsTalk Interviews
BioMarin and Ascendis settle patent disputes wi... - Pluang
BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea - PR Newswire
Ascendis Pharma (ASND) Shares Week 104 Data As FDA Clears Pediatric Achondroplasia Drug - simplywall.st
H.C. Wainwright initiates Ascendis Pharma stock coverage with buy rating - Investing.com
H.C. Wainwright initiates Ascendis Pharma stock coverage with buy rating By Investing.com - Investing.com India
This Ascendis Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday - Sahm
If You Invested $1000 In Ascendis Pharma Stock 10 Years Ago, You Would Have This Much Today - Benzinga
Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of TransCon® CNP (Navepegritide) at ISDS 2026 - Yahoo Finance
Ascendis Pharma (ASND) On Profitability, The Valuation Narrative Still Points To Upside - simplywall.st
Ascendis Pharma A/S (ASND) Stock Analysis: A Biotech Powerhouse with 23.63% Potential Upside - DirectorsTalk Interviews
Ascendis Pharma (ASND): Three New Drugs Are Turning This Biotech Into A Growth Machine - Yahoo Finance
Ascendis Pharma (ASND) Q2 2026 Earnings Call Transcript - AOL.com
Is Ascendis Pharma (ASND) Priced Too Richly After Recent Progress? - Yahoo Finance
Ascendis Pharma A/S (NASDAQ:ASND) Upgraded to Strong-Buy at BMO Capital Markets - MarketBeat
Ascendis Pharma (ASND) Reports Earnings And Trial Updates, Is It Fully Priced? - Yahoo Finance
Price to earnings forward of Ascendis Pharma A/S – NASDAQ:ASND - TradingView
Ascendis a new outperform at BMO on TransCon platform growth - Seeking Alpha
Penn Series Small Cap Growth Fund's Ascendis Pharma AS(ASND) Holding History - GuruFocus
BMO initiates Ascendis Pharma stock coverage with outperform rating By Investing.com - Investing.com Nigeria
BMO initiates Ascendis Pharma stock coverage with outperform rating - Investing.com
0.71%
2.84%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):